The head of Novartis Innovative Drugs China confirmed!

In recent days, two more multinational pharmaceutical companies have announced major personnel changes

On April 22, it was reported that Novartis has identified the regional heads of innovative drugs international, and Zhang Ying, president of Novartis Pharmaceuticals (China), has been appointed as the president and managing director of innovative drugs China

In recent years, Novartis has achieved steady growth in performance

Novartis said the streamlined organizational structure and operational setup supports Novartis' focus on pharmaceuticals to power the next phase of innovation, growth and productivity

Bayer is also accelerating the adjustment of product pipelines and staffing, especially strengthening its foothold in the field of oncology, investing heavily in expanding research and development pipelines, and collaborating with a number of gene therapy companies

At present, Bayer has launched 6 products and 10 indications in the global oncology market, with an important focus coming from the new drug Nubeqa for the treatment of prostate cancer

Notably, Bayer's prostate cancer product matrix is ​​growing, and in addition to Nubeqa, the prostate cancer radiotherapy drug Xofigo has been approved for the treatment of castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases patients with sexually transmitted diseases
.
Previously, Bayer also acquired exclusive rights to a differential alpha radionuclide therapy based on actinium-225 and a prostate-specific small molecule antigen (PSMA) targeting through the acquisition of Noria and subsidiary PSMA Therapeutics
.

Under the tide of global resource integration of multinational pharmaceutical giants, last year, Pfizer officially replaced the background LOGO of "Blue Pill", which has been used for more than 70 years, with two blue spirals in the shape of a circle.
The new LOGO marks Pfizer from diversification to focusing on R&D.
Shifts in prescription drugs and vaccines to prevent and treat disease
.
In March of this year, Johnson & Johnson announced that its medical device business was officially renamed "Johnson & Johnson Medical Technology" globally, marking the transformation of Johnson & Johnson Medical into an innovative enterprise centered on patients and driven by business growth
.

As an important driving force for the growth of global performance of multinational pharmaceutical companies, the potential of the Chinese market is self-evident, and China is accelerating its integration with the international market
.
In the financial reports released by multinational pharmaceutical companies in 2021, the revenue growth rates of Merck and Eli Lilly in China are as high as 60% and 41% respectively
.
In recent years, under the influence of multiple factors such as drug review reform, centralized procurement, and medical insurance negotiation, multinational pharmaceutical giants have also initiated a new round of structural adjustment, increased investment in China, focused on core therapeutic areas, and accelerated relying on innovative products.

.

Roche China has made adjustments one after another, upgraded and created a customer interaction business model "centered on the field of disease treatment"
.
In June last year, under the patient and disease-oriented trend, Roche started the road of "agile transformation" and established a "lymphoma sub-specialty innovation team", focusing on the standardization of lymphoma diagnosis and treatment in China and the survival benefits of lymphoma patients.
increase, and turn on the "ecosphere mode"
.
In December of the same year, Roche announced that it would set up two special areas in Guangdong Province and the Sichuan-Chongqing region to explore the "regional model"
.

Merck China merged the digital interaction and transformation and commercial operations divisions to form a new division of business excellence
.
MSD China also merged business operations and key account management to create a new business excellence department to accelerate the entry and listing of MSD China
.
In addition, a new data protection officer and chief transformation officer have been created
.

For multinational companies, a series of measures such as organizational structure adjustment, business line divestiture and merger, and replacement of executives have become the norm.
"Medicine Economic News" will continue to pay attention to how the Chinese market continues to adjust
.

Text editor: Chen Shuwen

Format editor: Chen Shuwen